title: Anti-human herpesvirus 6A/B IgG correlates with relapses and progression in multiple sclerosis.
abstract: OBJECTIVE
  To analyze the titers of the IgG and IgM antibodies against human herpesvirus 6A/B (HHV-6A/B) in multiple sclerosis (MS) patients treated with different disease modified therapies (DMTs) along two-years of follow-up.
  
  
  METHODS
  We collected 2163 serum samples from 596 MS; for 301 MS patients a 2-years follow-up was performed. Serum samples of 337 healthy controls were also analyzed. Anti-HHV-6A/B IgG and IgM were analyzed by ELISA (Panbio).
  
  
  RESULTS
  We found that 129/187 (69.0%) MS patients with a decrease of the anti-HHV-6A/B IgG titers after 2-years with DMTs were free of relapses and progression vs. 46/113 (40.7%) of MS patients with an increase of the anti-HHV-6A/B IgG titers (p = 0.0000015); the higher significance was found for natalizumab. Furthermore, we found that anti-HHV-6A/B IgG titers reached their highest value two weeks before the relapse (p = 0.0142), while the anti-HHV-6A/B IgM titers reached their highest value one month before the relapse (p = 0.0344).
  
  
  CONCLUSIONS
  The measurement of the anti-HHV-6A/B IgG titers could be a good biomarker of clinical response to the different DMTs. The increase of the anti-HHV-6A/B IgG and IgM titers predicts the upcoming clinical relapses. However, further longitudinal studies are needed to validate these results.
authors.affiliation: Servicio de Análisis Clínicos. Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
authors.forename: Isabel
authors.initials: I
authors.lastname: Ortega-Madueño
authors.affiliation: Servicio de Neurología. Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
authors.forename: Marta
authors.initials: M
authors.lastname: Garcia-Montojo
authors.affiliation: Servicio de Neurología. Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
authors.forename: Maria Inmaculada
authors.initials: MI
authors.lastname: Dominguez-Mozo
authors.affiliation: Servicio de Neurología. Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
authors.forename: Angel
authors.initials: A
authors.lastname: Garcia-Martinez
authors.affiliation: Servicio de Neurología. Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
authors.forename: Ana Maria
authors.initials: AM
authors.lastname: Arias-Leal
authors.affiliation: Servicio de Neurología. Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
authors.forename: Ignacio
authors.initials: I
authors.lastname: Casanova
authors.affiliation: Servicio de Neurología. Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
authors.forename: Rafael
authors.initials: R
authors.lastname: Arroyo
authors.affiliation: Servicio de Neurología. Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
authors.forename: Roberto
authors.initials: R
authors.lastname: Alvarez-Lafuente
mesh_terms: D000328:Adult; D057134:Antibodies, Neutralizing / Q000097:blood / Q000276:immunology; D000914:Antibodies, Viral / Q000276:immunology*; D015415:Biomarkers / Q000097:blood; D018450:Disease Progression; D005260:Female; D015654:Herpesvirus 6, Human / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood* / Q000276:immunology; D007075:Immunoglobulin M / Q000097:blood* / Q000276:immunology; D007155:Immunologic Factors / Q000627:therapeutic use; D016899:Interferon-beta / Q000276:immunology; D008297:Male; D009103:Multiple Sclerosis / Q000097:blood / Q000235:genetics / Q000628:therapy*; D000069442:Natalizumab / Q000627:therapeutic use; D012008:Recurrence
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D015415:Biomarkers; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007155:Immunologic Factors; D000069442:Natalizumab; D016899:Interferon-beta
references.citation: Eur J Neurol. 2010 Mar;17(3):470-8
references.pmid: 20050906
references.citation: JAMA. 2005 May 25;293(20):2496-500
references.pmid: 15914750
references.citation: Lancet. 2009 Oct 31;374(9700):1503-11
references.pmid: 19815268
references.citation: Acta Neurol Scand. 2005 Dec;112(6):395-402
references.pmid: 16281923
references.citation: Mult Scler. 2002 May;8(3):237-42
references.pmid: 12120696
references.citation: Mult Scler. 2012 Jun;18(6):799-806
references.pmid: 22084489
references.citation: Curr Opin Neurol. 2009 Jun;22(3):201-6
references.pmid: 19359987
references.citation: J Infect Dis. 2003 May 1;187(9):1365-76
references.pmid: 12717617
references.citation: Neurology. 2005 Apr 26;64(8):1336-42
references.pmid: 15851719
references.citation: Semin Neurol. 2011 Jul;31(3):307-16
references.pmid: 21964847
references.citation: Eur J Neurol. 2010 Jan;17(1):129-35
references.pmid: 19659749
references.citation: J Neurol Sci. 2008 Sep 15;272(1-2):8-19
references.pmid: 18620708
references.citation: JAMA. 2001 Dec 26;286(24):3083-8
references.pmid: 11754673
references.citation: Eur Neurol. 2004;52(2):87-91
references.pmid: 15273429
references.citation: Ann Neurol. 2000 Mar;47(3):306-13
references.pmid: 10716249
references.citation: J Mol Med (Berl). 1997 Feb;75(2):89-94
references.pmid: 9083926
references.citation: Nat Med. 1997 Dec;3(12):1394-7
references.pmid: 9396611
references.citation: Neurology. 2010 Jan 5;74 Suppl 1:S25-30
references.pmid: 20038760
references.citation: J Neurol. 2004 Jun;251 Suppl 2:II15-II24
references.pmid: 15264108
references.citation: N Engl J Med. 2006 Mar 2;354(9):899-910
references.pmid: 16510744
references.citation: Lancet Neurol. 2009 Nov;8(11):987-97
references.pmid: 19748319
references.citation: Neurology. 1995 Jul;45(7):1268-76
references.pmid: 7617181
references.citation: Mult Scler. 2013 Oct;19(11):1454-61
references.pmid: 23439578
references.citation: Eur J Neurol. 2011 Aug;18(8):1027-35
references.pmid: 21518144
references.citation: Methods Enzymol. 1986;119:558-73
references.pmid: 2429157
references.citation: Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7440-4
references.pmid: 7638210
references.citation: N Engl J Med. 2000 Sep 28;343(13):938-52
references.pmid: 11006371
references.citation: Nat Rev Drug Discov. 2007 Dec;6(12):975-90
references.pmid: 18049472
references.citation: Brain Pathol. 2006 Jan;16(1):20-7
references.pmid: 16612979
references.citation: J Infect Dis. 2000 Nov;182(5):1321-5
references.pmid: 11023456